Prognostic/predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: Back to the future?

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4451-4453

  Bhargava, Rohit ^a   Brufsky, Adam M ^a,b   Davidson, Nancy E ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

CANCER CLASSIFICATION; CANCER PROGNOSIS; DIAGNOSTIC TEST; EDITORIAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; TREATMENT PLANNING;

ANDROSTADIENES; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN; TISSUE ARRAY ANALYSIS;

EID: 84871738326     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.6955     Document Type: Editorial

References (17)

1. Bartlett JMS, Bloom KJ, Piper T, et al: Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the Tamoxifen versus Exemestane Adjuvant Multicenter pathology study. J Clin Oncol 30:4477-4484, 2012
2. Ring BZ, Seitz RS, Beck R, et al: Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24:3039-3047, 2006 (Pubitemid 46638938)
3. Bartlett JM, Thomas J, Ross DT, et al: Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 12:R47, 2010
4. Ross DT, Kim CY, Tang G, et al: Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res 14:6602-6609, 2008
5. Jerevall PL, Ma XJ, Li H, et al: Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104:1762-1769, 2011
6. Ma XJ, Salunga R, Dahiya S, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601-2608, 2008
7. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
8. Hicks DG, Boyce BF: The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem 87:14-17, 2012
9. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R: The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 25:1098-1105, 2012
10. Viana CR, Neto CS, Kerr LM, et al: The interference of cold ischemia time in the quality of total RNA from frozen tumor samples. Cell Tissue Bank [epub ahead of print on May 5, 2012]
11. Tang G, Cuzick J, Costantino JP, et al: Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29:4365-4372, 2011
12. Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278, 2011
13. Galea MH, Blamey RW, Elston CE, et al: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207-219, 1992
14. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes: Dealing with the diversity of breast cancer - Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747, 2011
15. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
16. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
17. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010